Male Infertility Market: Asia-Pacific Size & Analysis

1. Male Infertility Market: Asia-Pacific Size & Analysis As per a study by WHO, approximately 17.5% of the global adult population (around 1 in 6) experience infertility. Among these, male factors are responsible for around 20-30% of all infertility cases. Over the past decade, sperm count has halved globally owing to irregular morphology, delayed sperm mortality, alcohol consumption, smoking, etc. This high prevalence has elevated the global demand for effective infertility treatments, including assisted reproductive technology (ART). As per our estimates, the global male infertility market is set to advance with a CAGR of 4.81% during the forecast period 2023-2030, garnering $5780.03 million by 2030. Despite the stigma, infertility research has come a long way, with one aspect gaining recognition - male factor infertility. Studies, including those published by the Medical Journal of Australia in 2022, reveal that male infertility connects to cancer, early mortality, and other related medical issues. As a result, cutting-edge test types have been developed, including oxidative stress analysis, oxidative stress analysis, etc. As male infertility continues to be a prevalent concern worldwide, breakthroughs in research have enabled better diagnosis and treatment options, especially in developing economies.

2. Asia-Pacific: A Forthcoming Leader in Male Infertility Treatment From increasing disposable income to technological advancements, male infertility treatments have soared across various nations, especially South Korea, China, and India. As per our analysis, the Asia-Pacific male infertility market is estimated to advance with a CAGR of 5.38% during the forecast period 2023-2030, emerging as the fastest-growing region. In terms of advancements, a research team at Kumamoto University introduced a cell sorter with microfluidic chip technology that minimized negative effects on cells and sperm. Another initiative includes the smartphone platform YO Home Sperm Test, introduced by Medical Electronic Systems in India. As the region continues to witness cutting-edge innovations, stakeholders can look forward to a promising landscape for male infertility treatments and services. China leads with $258.11 million in 2022 An increased prevalence of diseases such as diabetes, genetic abnormalities, and infections like chlamydia, gonorrhea, mumps, and HIV has been observed, leading to a rise in male infertility cases. This has elevated the adoption of assisted reproductive technology (ART) , especially IVF. As of June 2021, China boasts over 529 ART-approved medical facilities and around 27 sperm banks. In terms of treatment, ART dominated with $2299.32 million in 2022. From Intracytoplasmic Sperm Injection (ICSI) and in vitro fertilization (IVF) to cryopreservation and Preimplantation Genetic Diagnosis (PGD), ART encompasses a variety of treatments. Recent developments in ART have further expanded its capabilities and accessibility. For instance, a research team led by the University of Adelaide, in collaboration with Fertilis, launched a groundbreaking micro-device that offers a new reproductive therapy option for males with low sperm counts. Another contributing factor includes proactive government steps to offer free fertility therapy to individuals through the National Insurance Program. The expansion of coverage by the National Healthcare Security Administration, announced in 2023, aims to provide financial assistance for couples seeking fertility treatments, including various ART methods. South Korea Witnessing fastest growth at 8.51% of CAGR in 2023-2030 From lifestyle changes to the prevalence of diseases like diabetes and cancer, the landscape of male infertility is significantly transforming in South Korea. According to the National Center for Biotechnology Information, in 2020, a staggering 6.05 million Koreans aged 30 and older, constituting 19.2% of males, were affected by diabetes mellitus. Diabetes, a significant health issue, is increasingly impacting male fertility. Cancer, another critical health concern, also plays a role in the rising number of male infertility cases. Estimates highlight that out of the 230,317 newly diagnosed cancer cases in Korea in 2020, a substantial 121,263 were in men. To address this growing challenge, numerous commercial companies and public institutions offer cutting-edge male infertility treatments. For instance, the CHA Fertility Centre in South Korea provides advanced

3. treatments like semen analysis, karyotyping, and microsurgical multiple testicular sperm extraction (M-TESE) for infertile men. The Shift from Conventional Approaches to Minimally Invasive Procedures When it comes to surgical procedures, the focus has always been on safety and patient outcomes. In this regard, minimally invasive techniques have gained popularity in reducing postoperative patient morbidity compared to conventional approaches. In the realm of assisted reproductive technology, these advancements have paved the way for a range of procedures, from intrauterine insemination (IUI) to cutting-edge intracytoplasmic sperm injection (ICSI). While these treatments have gained momentum, medical micro-robotics is another notable technology on the horizon. Controlled by external physical fields like magnetism or ultrasound, these microrobots can perform various tasks, making them more than passive carriers. Hence, advancements in minimally invasive procedures are expected to lower infertility treatment costs, further opening avenues for the male infertility treatment market. FAQs: Q1) Which are the key test types in the male infertility market? DNA fragmentation technique, oxidative stress analysis, sperm agglutination, computer- assisted semen analysis, and microscopic examination are among the key male infertility test types. Q2) Which countries are considered in the Asia-Pacific male infertility market? China, Japan, India, South Korea, ASEAN Countries, and Australia & New Zealand are considered in the regional market.